However, the results of initial clinical trials with CD19-antibodies were disappointing [5, 8], presumably due at least in part to a far lower surface density of CD19 on the malignant cells than of CD20 on lymphoma cells, the target antigen for the clinically successful antibody Rituximab. The gene discussed is CD19; the disease is lymphoma.